Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
Peter Zdziarski, Founder and Marketing Director of Glanzmann Thrombasthenia Advocacy Network, shared a post on LinkedIn:
“NovoSeven has been a lifesaving treatment for many people with Glanzmann Thrombasthenia, but I want those in the community to know that it’s important to remember that no medication is perfect.
Like all newer drugs, NovoSeven passed clinical trials, but long-term effects, rare complications, and real-world outcomes still take time to understand fully.
Approval does not mean a treatment is 100% effective or risk-free.
I hope that when adverse events or unexpected outcomes occur, Novo Nordisk thoroughly investigates them and shares those findings publicly. The GT community benefits from transparency, whether the results are positive or negative.
I always say:
Read the fine print, no matter how long or small; ask questions; and understand both the benefits and risks of any treatment you use.
The more we learn, the better care future GT patients will receive.”
Other posts featuring Peter Zdziarski on Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients